|
|
|
04.08.25 - 13:06
|
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted six newly-hired employees inducement options to purchase an aggregate of 44,000 shares of KalVista common stock on August 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date.
One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.07.25 - 13:06
|
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results (Business Wire)
|
|
|
– Received FDA approval of EKTERLY® (sebetralstat)—the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway –
– Six additional global regulatory submissions under review –
– Entered licensing agreements for sebetralstat commercialization in Japan and Canada –
– $220.6M in cash, providing runway into 2027 –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.
“The FDA approval of EKTERLY represents a major milestone—not only as the first commercial product for KalVista, but more importantly, as the first and only oral on-demand therapy for people living with HAE,” said Ben Palleiko, CEO of KalVista Pharmaceuticals. “EKTERLY delivers a long-awaited treatment that is safe, effective, and easy to administer. Our commercial team is actively engaging in the field, leveraging their expertise to ...
|
|
|
|
|
|
|
|
|
07.07.25 - 14:30
|
KalVista Pharmaceuticals: +123% Rendite nach SDP-Tipp (Sharedeals)
|
|
|
Mit KalVista Pharmaceuticals gab heute einer unserer sharedealsPlus-Tipps die Zulassung seines Medikaments Ekterly bekannt. Die Aktie schießt noch einmal kräftig in die Höhe. Eine Rendite von bis zu 123% war für unsere Mitglieder innerhalb von nur sieben Monaten möglich. Mit „AntonH“ hatte einer unserer populärsten sharedealsPlus-Nutzer der Community am 6. Januar dieses Jahr eine unmissverständliche […]
The post KalVista Pharmaceuticals: +123% Rendite nach SDP-Tipp first appeared on sharedeals.de....
|
|
|
|
|
07.07.25 - 14:01
|
KalVista Shares Surge as FDA Approves New Drug After Delay (Bloomberg)
|
|
|
KalVista Pharmaceuticals Inc. shares rose 19% early Monday after the company said it received US Food and Drug Administration approval for its pill for hereditary angioedema, a rare and potentially deadly condition that causes severe swelling throughout the body....
|
|
|
02.07.25 - 22:06
|
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on July 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date.
One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)...
|
|
|
|
|
|
|
|
|
03.06.25 - 22:06
|
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 50,000 shares of KalVista common stock on June 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date.
One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
